Meta-analysis of Mifepristone in the Treatment of Abnormal Uterine Bleeding in Chinese Women during Perimenopausal Period
10.6039/j.issn.1001-0408.2017.36.17
- VernacularTitle:米非司酮治疗中国女性围绝经期异常子宫出血有效性的Meta分析
- Author:
Binchi LIAO
1
;
Qunxia MAO
Author Information
1. 国家食品药品监督管理总局高级研修学院
- Keywords:
Mifepristone;
Perimenopause period;
Abnormal uterine bleeding;
Chinese women;
Meta-analysis;
Therapeutic efficacy
- From:
China Pharmacy
2017;28(36):5101-5105
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the effectiveness of mifepristone in the treatment of abnormal uterine bleeding in Chinese women during perimenopause period,and to provide evidence-based reference in clinic.METHODS:Retrieved from CJFD,SinoMed,VIP,Wanfang database,randomized controlled trials (RCTs) about mifepristone in the treatment of abnormal uterine bleeding in Chinese women during perimenopause period were collected,data extraction was conducted for clinical studies meeting inclusion criteria.Meta-analysis was conducted by using Stata 8.0 statistical software after quality evaluation with Cochrane manual 5.1.0.RESULTS:A total of 49 RCTs were included,involving 5 082 patients.Meta-analysis showed that the response rate of mifepristone high-dose group (12.5 mg/d)was significantly higher than that of mifepristone low-dose group (≤ 6.5 mg/d)[OR=2.13,95％ CI(1.53,2.97),P＜0.001],and response rate of mifepristone group was significantly higher than that of progesterone drug group [OR=6.05,95％CI(3.92,9.34),P＜0.001].There was no statistical significance in response rate between mifepristone group and estrogen drug group [OR=1.52,95％ CI (0.45,5.16),P=0.499].CONCLUSIONS:Mifepristone is better than progesterone drug and similar to hormone drug in the treatment of abnormal uterine bleeding during perimenopause period.High-dose of mifepristone is better than low-dose of mifepristone in the treatment of abnormal uterine bleeding during perimenopause period.
